drugset / Trial / NCT00220311

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

NCT00220311

Phase 4 Completed 10 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in untreated chronic lymphocytic leukemia (CLL) patients with anemia and/or thrombocytopenia.

Timeline

Start
2000-11
Primary completion
2005-09
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludarabine Small molecule